Radar Finance | Written by Feng Xiuyu | Edited by Li Yihui
On February 25th, United Imaging Healthcare (688271) released its 2025 annual performance forecast. During the reporting period, it achieved operating revenue of 13.821 billion yuan, a year-on-year increase of 34.18%. Net profit attributable to shareholders of the listed company was 1.888 billion yuan, up 49.60% year-on-year. After excluding non-recurring gains and losses, net profit attributable to shareholders was 1.788 billion yuan, a 77.01% increase. Basic earnings per share were 2.29 yuan, up 48.70% year-on-year.
According to Tianyancha, United Imaging Healthcare was established on March 21, 2011, with a registered capital of 824.157988 million yuan. The legal representative is Zhang Qiang, and the registered address is No. 2258 Chengbei Road, Jiading District, Shanghai. Its main business is providing high-performance medical imaging equipment, radiotherapy products, life science instruments, and digital and intelligent healthcare solutions worldwide.
Currently, the company’s chairman is Zhang Qiang, the secretary is Tao Cai, with 8,420 employees, and the actual controller is Xue Min.
The company has stakes in 37 subsidiaries, including United Imaging Healthcare Kazakhstan Limited Liability Partnership, PT UIH Indonesia Solution, UNITED IMAGING HEALTHCARE COLOMBIA S.A.S, UNITED IMAGING HEALTHCARE PTE. LTD., and UNITED IMAGING HEALTHCARE POLAND SPKA Z OGRANICZONODPOWIEDZIALNOCI.
In terms of performance, the company’s operating revenue was 9.238 billion yuan in 2022, 11.411 billion yuan in 2023, and 10.3 billion yuan in 2024, with year-on-year growth rates of 27.36%, 23.52%, and -9.73%, respectively. Net profit attributable to the parent was 1.656 billion yuan, 1.974 billion yuan, and 1.262 billion yuan, with year-on-year growth rates of 16.86%, 19.21%, and -36.09%. During the same period, the company’s asset-liability ratio was 27.81%, 25.48%, and 29.00%.
Regarding risks, Tianyancha data shows the company has 213 internal Tianyan risks, 162 surrounding risks, 117 historical risks, and 1,565 early warning risks.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
United Imaging Healthcare Quick Performance Report: Net profit attributable to parent company in 2025 increased by 49.60% year-on-year
Radar Finance | Written by Feng Xiuyu | Edited by Li Yihui
On February 25th, United Imaging Healthcare (688271) released its 2025 annual performance forecast. During the reporting period, it achieved operating revenue of 13.821 billion yuan, a year-on-year increase of 34.18%. Net profit attributable to shareholders of the listed company was 1.888 billion yuan, up 49.60% year-on-year. After excluding non-recurring gains and losses, net profit attributable to shareholders was 1.788 billion yuan, a 77.01% increase. Basic earnings per share were 2.29 yuan, up 48.70% year-on-year.
According to Tianyancha, United Imaging Healthcare was established on March 21, 2011, with a registered capital of 824.157988 million yuan. The legal representative is Zhang Qiang, and the registered address is No. 2258 Chengbei Road, Jiading District, Shanghai. Its main business is providing high-performance medical imaging equipment, radiotherapy products, life science instruments, and digital and intelligent healthcare solutions worldwide.
Currently, the company’s chairman is Zhang Qiang, the secretary is Tao Cai, with 8,420 employees, and the actual controller is Xue Min.
The company has stakes in 37 subsidiaries, including United Imaging Healthcare Kazakhstan Limited Liability Partnership, PT UIH Indonesia Solution, UNITED IMAGING HEALTHCARE COLOMBIA S.A.S, UNITED IMAGING HEALTHCARE PTE. LTD., and UNITED IMAGING HEALTHCARE POLAND SPKA Z OGRANICZONODPOWIEDZIALNOCI.
In terms of performance, the company’s operating revenue was 9.238 billion yuan in 2022, 11.411 billion yuan in 2023, and 10.3 billion yuan in 2024, with year-on-year growth rates of 27.36%, 23.52%, and -9.73%, respectively. Net profit attributable to the parent was 1.656 billion yuan, 1.974 billion yuan, and 1.262 billion yuan, with year-on-year growth rates of 16.86%, 19.21%, and -36.09%. During the same period, the company’s asset-liability ratio was 27.81%, 25.48%, and 29.00%.
Regarding risks, Tianyancha data shows the company has 213 internal Tianyan risks, 162 surrounding risks, 117 historical risks, and 1,565 early warning risks.